NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials Network

Information

  • Research Project
  • 8846077
  • ApplicationId
    8846077
  • Core Project Number
    U10CA180863
  • Full Project Number
    5U10CA180863-02
  • Serial Number
    180863
  • FOA Number
    RFA-CA-12-504
  • Sub Project Id
  • Project Start Date
    5/6/2014 - 10 years ago
  • Project End Date
    2/28/2019 - 5 years ago
  • Program Officer Name
    MOONEY, MARGARET M
  • Budget Start Date
    3/1/2015 - 9 years ago
  • Budget End Date
    2/29/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    02
  • Suffix
  • Award Notice Date
    3/18/2015 - 9 years ago

NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials Network

DESCRIPTION (provided by applicant): The overall goal of the NCTN Program is to conduct definitive, randomized, late phase clinical treatment trials and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials, as part of the NCI's overall clinical research program for adults and children with cancer. The mission of the NCIC CTG is to develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease. The overlaps of these goals create a rationale for a Canadian Collaborating Clinical Trials Network. This rationale is further supported by similar societal expectations by Canadians and Americans for improved health outcomes and similar respective strategic priorities of NCIC CTG and the NCTN that recognize that new understandings of the molecular basis of carcinogenesis have the potential to advance health care delivery, including through improved therapeutic targeting of the cancer cell and better identification of therapies for individual patients. The specific objectives of NCIC CTG to collaborate with NCI/CTEP and US-based groups, through its newly-formed National Clinical Trials Network Program, to develop new Intergroup trials under NCIC CTG leadership and to ensure more rapid accrual to trials led by US-based groups, to enhance the scientific content of these trials through evaluation of additional endpoints and to contribute to new understandings of clinical trial methodology and analysis. This aim is facilitated by NCIC CTG's unique information technology supports and understandings of the Canadian regulatory environment. The aims of this application are to facilitate Canadian leadership of NCTN trials that represent value from the perspective of expenditure of U.S. federal dollars and to conduct U.S.-led NCTN trials in Canada.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U10
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    3219073
  • Indirect Cost Amount
    101060
  • Total Cost
    3135983
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:3135983\
  • Funding Mechanism
    OTHER RESEARCH-RELATED
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    QUEEN'S UNIVERSITY AT KINGSTON
  • Organization Department
  • Organization DUNS
    207884032
  • Organization City
    KINGSTON
  • Organization State
    ON
  • Organization Country
    CANADA
  • Organization Zip Code
    K7L 3N6
  • Organization District
    CANADA